Cancer clinical trials in the region Pays de la Loire
413 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lung cancer
#NCT06881784
#2024-518154-16-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Other KRAS
HRAS
KRAS G12C
KRAS non G12C
KRAS G12D
NRAS
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
16 recruiting sites
Revolution Medicines, Inc.
Phase 3
Lung cancer
#NCT06623422
#2023-506327-29-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
7 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Colon cancer
Rectal cancer
#NCT06252649
#2022-502352-31-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
16 recruiting sites
Amgen
Phase 3
Breast cancer
#NCT06790693
#2024-516162-11-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Hoffmann-La Roche
Phase 3
Breast cancer
#NCT06790693
#2024-516162-11-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
12 recruiting sites
Hoffmann-La Roche
Phase 3
Breast cancer
#NCT06492616
#2024-515445-42-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Excluded previous treatments at localized stage
Hormone therapy
21 recruiting sites
Stemline Therapeutics, Inc.
Phase 3
Acute leukemia
#NCT05429632
#2024-512752-38-00
Required histologic types
Acute myeloid leukemia (AML)
Required number of previous lines of therapy
None
4 recruiting sites
Priothera SAS
Phase 3
Acute leukemia
#NCT06852222
#2024-520154-38-00
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
KMT2A
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
13 recruiting sites
Janssen
Phase 3
Acute leukemia
#NCT06578247
#2023-507936-20-00
Required histologic types
Acute myeloid leukemia (AML)
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
FLT3-ITD
BCR-ABL
Excluded previous treatments
Chemotherapy
15 recruiting sites
Daiichi Sankyo
Phase 3
Endometrial cancer
#NCT06952504
#2024-519331-42-00
Required histologic sub types
Endometrioid adenocarcinoma
Serous adenocarcinoma
Clear cell carcinoma
Dedifferentiated and undifferentiated endometrial ...
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
MSI/dMMR
Excluded previous treatments at localized stage
Immunotherapy
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Antibody Drug Conjugates (ADC)
10 recruiting sites
Merck Sharp & Dohme LLC